Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer
ISRCTN86043495Phase 3Completed
- Sponsor
- Michelangelo Foundation
- Start
- Jun 2002
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of trastuzumab in breast cancer (3 arms), sponsored by Michelangelo Foundation. Primary endpoint: Event-free survival. Started Jun 2002; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN86043495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN86043495.